Introduction

Pfizer’s aggressive marketing activity to support the launch of Detrol (tolterodine) also successfully raised wider disease awareness. With the two market leading drugs both suffering from poor side-effect profiles, and considerable scope for improved efficacy, there is still considerable unmet need in the market. 

Scope

Overview of epidemiology of urinary incontinence, by sub-indications, with an evaluation of the potential for expanding the diagnosed population 

Review of the performance of the leading drugs in the market, Pfizer’s Detrol (tolterodine) and ALZA’s Ditropan XL (oxybutynin chloride) 

Analysis of the potential of Yamanouchi’s Vesicare (solifenacin succinate), Novartis’s Enablex (darifenacin) and Eli Lilly’s duloxetine 

Report Highlights

Fighting off strong competition from Yamanouchi’s Vesicare and Enablex from Novartis, Pfizer’s Detrol will maintain its position as urinary incontinence market leader. 

Of the two drugs expected to launch in 2004, Vesicare is expected to prove more popular than Enablex, backed up by favorable results from a head-to-head study with Detrol. Thanks in part to this, its sales will surge to $971m by 2011 while Enablex will reach $743m. 

In the stress urinary incontinence sub-indication, Eli Lilly’s duloxetine will enjoy considerable success as the market expands, with sales of $488m forecast for 2011. 

Reasons to Purchase

Gauge the potential of the key late-stage pipeline products 

Understand the factors driving the urinary incontinence market 

Evaluate the patient potential in each of the key urinary incontinence sub-indications 

TABLE OF CONTENTS 

EXECUTIVE SUMMARY 5

Introduction 5

Scope and coverage of the Brief 5

Key findings about the the topic 6

EPIDEMIOLOGY 8

Definition 8

Patient potential 12

Diagnosis 16

OPPORTUNITIES FOR PHARMA 20

Pharmacological therapies with improved clinical profiles 20

Effective drug treatments for stress incontinence 21

THE CURRENT MARKET 22

Detrol (tolterodine) 22

Ditropan XL (oxybutynin chloride) 24

Opportunities for pipeline products 25

PIPELINE POTENTIAL 26

Pipeline overview 26

Vesicare (solifenacin succinate) 27

Enablex (darifenacin) 29

Duloxetine 30

MARKET FORECASTS 33

APPENDIX 35

Bibliography 35 

December 2003, 37pages 

Publisher: Datamonitor Womens Health Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Womens_Health.html#a381